TNGX vs. EBS

Last updated Jun 4, 2026

TNGX (Tango Therapeutics, Inc.) and EBS (Emergent BioSolutions Inc.) are both stocks. Both are in the Healthcare sector — TNGX in Biotechnology, EBS in Drug Manufacturers - Specialty & Generic. Over the past 5 years, TNGX returned 14.42%/yr vs -34.22%/yr for EBS. At a 0.24 correlation, their price movements are largely independent.

Performance

TNGX vs. EBS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tango Therapeutics, Inc. (TNGX) and Emergent BioSolutions Inc. (EBS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TNGX achieves a 142.33% return, which is significantly higher than EBS's -35.84% return.

TNGX

• 1D: -0.14%
• 1M: -5.46%
• YTD: 142.33%
• 6M: 124.35%
• 1Y: 562.65%
• 3Y*: 88.81%
• 5Y*: 14.42%
• 10Y*: —

EBS

• 1D: -3.41%
• 1M: -7.14%
• YTD: -35.84%
• 6M: -31.64%
• 1Y: 23.71%
• 3Y*: -1.27%
• 5Y*: -34.22%
• 10Y*: -15.21%

*Multi-year figures are annualized to reflect compound growth (CAGR)

TNGX vs. EBS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
TNGX Tango Therapeutics, Inc.	142.33%	186.73%	-68.79%	36.55%	-33.73%	-4.37%	11.83%
EBS Emergent BioSolutions Inc.	-35.84%	29.29%	298.33%	-79.68%	-72.83%	-51.48%	-16.24%

Correlation

The correlation between TNGX and EBS is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.28
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.25
Correlation (All Time) Calculated using the full available price history since Sep 4, 2020	0.24

Fundamentals

EPS TNGX : -$0.89 EBS : -$0.37
PS Ratio TNGX : 45.32 EBS : 0.49
Total Revenue (TTM) TNGX : $56.99M EBS : $676.80M
Gross Profit (TTM) TNGX : $55.33M EBS : $292.40M
EBITDA (TTM) TNGX : -$111.92M EBS : $126.60M

Return for Risk

TNGX vs. EBS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TNGX

TNGX Risk / Return Rank: 98
TNGX Sharpe Ratio Rank: 99
TNGX Sortino Ratio Rank: 98
TNGX Omega Ratio Rank: 96
TNGX Calmar Ratio Rank: 99
TNGX Martin Ratio Rank: 99

EBS

EBS Risk / Return Rank: 54
EBS Sharpe Ratio Rank: 51
EBS Sortino Ratio Rank: 56
EBS Omega Ratio Rank: 57
EBS Calmar Ratio Rank: 53
EBS Martin Ratio Rank: 52

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TNGX vs. EBS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tango Therapeutics, Inc. (TNGX) and Emergent BioSolutions Inc. (EBS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TNGX	EBS	Difference
Sharpe ratio Return per unit of total volatility	6.52	0.29	+6.23
Sortino ratio Return per unit of downside risk	5.05	1.11	+3.94
Omega ratio Gain probability vs. loss probability	1.63	1.15	+0.48
Calmar ratio Return relative to maximum drawdown	19.41	0.55	+18.87
Martin ratio Return relative to average drawdown	51.43	1.03	+50.40
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TNGX vs. EBS - Sharpe Ratio Comparison

The current TNGX Sharpe Ratio is 6.52, which is higher than the EBS Sharpe Ratio of 0.29. The chart below compares the historical Sharpe Ratios of TNGX and EBS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TNGX	EBS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	6.52	0.29	+6.23
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.15	-0.34	+0.48
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.15	-0.03	+0.17

Drawdowns

TNGX vs. EBS - Drawdown Comparison

The maximum TNGX drawdown since its inception was -93.64%, smaller than the maximum EBS drawdown of -98.89%. Use the drawdown chart below to compare losses from any high point for TNGX and EBS.

Drawdown Indicators

	TNGX	EBS	Difference
Max Drawdown Largest peak-to-trough decline	-93.64%	-98.89%	+5.25%
Max Drawdown (1Y) Largest decline over 1 year	-29.24%	-43.53%	+14.29%
Max Drawdown (3Y) Largest decline over 3 years	-91.46%	-84.58%	-6.88%
Max Drawdown (5Y) Largest decline over 5 years	-93.64%	-97.73%	+4.09%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.89%	—
Current Drawdown Current decline from peak	-22.69%	-94.12%	+71.43%
Average Drawdown Average peak-to-trough decline	-48.20%	-41.07%	-7.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.02%	23.11%	-12.09%

Volatility

TNGX vs. EBS - Volatility Comparison

Tango Therapeutics, Inc. (TNGX) has a higher volatility of 27.67% compared to Emergent BioSolutions Inc. (EBS) at 17.24%. This indicates that TNGX's price experiences larger fluctuations and is considered to be riskier than EBS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TNGX	EBS	Difference
Volatility (1M) Calculated over the trailing 1-month period	27.67%	17.24%	+10.43%
Volatility (6M) Calculated over the trailing 6-month period	64.54%	47.98%	+16.56%
Volatility (1Y) Calculated over the trailing 1-year period	91.07%	82.42%	+8.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	99.00%	102.17%	-3.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.52%	79.95%	+13.57%

Dividends

TNGX vs. EBS - Dividend Comparison

Neither TNGX nor EBS has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
EBS Emergent BioSolutions Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.65%
TNGX Tango Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both TNGX and EBS in my portfolio?

TNGX and EBS have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TNGX or EBS?

TNGX has higher volatility (27.67%) compared to EBS (17.24%). In terms of maximum drawdown, TNGX dropped -93.64% vs EBS's -98.89%.

Which has better risk-adjusted returns?

TNGX currently has the higher Sharpe Ratio (6.52 vs 0.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.